Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

TARGET: A Phase II, Open-Label, Single-Arm Study of 5-Year Adjuvant Osimertinib in Completely Resected EGFR-Mutated Stage II to IIIB NSCLC Post Complete Surgical Resection
Ross A. Soo, Filippo de Marinis, Ji‐Youn Han, et al.
Clinical Lung Cancer (2023) Vol. 25, Iss. 1, pp. 80-84
Open Access | Times Cited: 10

Showing 10 citing articles:

Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer
Roy S. Herbst, Thomas John, Christian Grohé, et al.
Nature Medicine (2025)
Open Access | Times Cited: 1
Top advances of the year: Targeted therapy for lung cancer
Maisam Makarem, Pasi A. Jänne
Cancer (2024) Vol. 130, Iss. 19, pp. 3239-3250
Closed Access | Times Cited: 6
Osimertinib in the Treatment of Epidermal Growth Factor Receptor-Mutant Early and Locally Advanced Stages of Non-Small-Cell Lung Cancer: Current Evidence and Future Perspectives
Antonello Veccia, Mariachiara Dipasquale, M. Lorenzi, et al.
Cancers (2025) Vol. 17, Iss. 4, pp. 668-668
Open Access
Place des thérapies ciblées en situation adjuvante au cours des cancers bronchiques non à petites cellules localisés
Nicolas Girard
Bulletin du Cancer (2025) Vol. 112, Iss. 3, pp. 3S46-3S51
Closed Access
Updates on the treatment of epidermal growth factor receptor‐mutant non–small cell lung cancer
Jinyong Kim, Sehhoon Park, Bo Mi Ku, et al.
Cancer (2025) Vol. 131, Iss. S1
Closed Access
A narrative review on perioperative systemic therapy in non-small cell lung cancer
Robert Hsu, Zhaohui Arter, Darin Poei, et al.
Exploration of Targeted Anti-tumor Therapy (2024) Vol. 5, Iss. 4, pp. 931-954
Open Access | Times Cited: 3
Management of Non-Metastatic Non-Small Cell Lung Cancer (NSCLC) with Driver Gene Alterations: An Evolving Scenario
Valeria Fuorivia, Ilaria Attili, Carla Corvaja, et al.
Current Oncology (2024) Vol. 31, Iss. 9, pp. 5121-5139
Open Access | Times Cited: 3
The Role of ctDNA in the Management of Non-Small-Cell Lung Cancer in the AI and NGS Era
José Luís Costa, Alexandro Membrino, Carol Zanchetta, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 24, pp. 13669-13669
Open Access | Times Cited: 1
Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus Survey.
Sai‐Hong Ignatius Ou, Xiuning Le, Misako Nagasaka, et al.
Lung Cancer Targets and Therapy (2024) Vol. Volume 15, pp. 87-114
Open Access
Alectinib in Early-Stage Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: Current Evidence and Future Challenges
Diego Cortinovis, Alessandro Leonetti, Alessandro Morabito, et al.
Cancers (2024) Vol. 16, Iss. 14, pp. 2610-2610
Open Access
Page 1

Scroll to top